Company Description
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits.
The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E.
coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups.
In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station.
The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
| Country | United States |
| Founded | 1983 |
| IPO Date | Jun 21, 1991 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Jonathan Mazelsky |
Contact Details
Address: One IDEXX Drive Westbrook, Maine 04092 United States | |
| Phone | 207 556 0300 |
| Website | idexx.com |
Stock Details
| Ticker Symbol | IDXX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874716 |
| CUSIP Number | 45168D104 |
| ISIN Number | US45168D1046 |
| Employer ID | 01-0393723 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Jonathan J. Mazelsky | President, Chief Executive Officer and Director |
| Brian P. McKeon | Executive Vice President and Special Advisor |
| Michael J. Lane | Executive Vice President and GM Global Reference Laboratories, Diagnostic Solutions and Information Technology |
| Dr. Nimrata Khatra Hunt P.E., Ph.D. | Executive Vice President Global Strategy and Commercial |
| Andrew Emerson | Executive Vice President, Chief Financial Officer and Treasurer |
| Bob Asmann | Senior Vice President of Global Operations |
| Jeffery D. Chadbourne | Senior Vice President of Commercial Finance and Sales Operations |
| Ken Grady | Senior Vice President and Chief Information Officer |
| Sharon E. Underberg J.D. | Executive Vice President, General Counsel, and Corporate Secretary |
| Julie Godon | Senior Vice President and Global Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 21, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 144 | Filing |
| Feb 7, 2025 | 144 | Filing |
| Feb 3, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 144 | Filing |
| Nov 21, 2024 | 8-K | Current Report |